100 HOT TOPICS FOR DISSERTATION FOR PG DIPLOMA/ DEGREE IN REGULATORY AFFAIRS



Similar documents
INSIDE STORY FOR REVIEW OF DMF AND DOSSIERS BY REGULATORY AUTHORITIES. (Part I: ANDA, NDA & DMF)

RISK IDENTIFICATION,ASSESSMENT & MITIGATION TEMPLATE

TYPICAL FDA COMMENTS ON IMPURITY PROFILING IN CTD/CEP/DMF SUBMISSIONS

RAPS ONLINE UNIVERSITY

GDUFA (GENERIC DRUG USER FEE ACT): Q&A TELECONFERENCE 26 TH JUNE 2012

GDUFA (Generic Drug User Fee Act): Q&A Session 2 by teleconference

Qualification of Excipients for Use in Pharmaceuticals

CTD Dossier Preparation. Sr.Manager-Regulatory Affairs

GMP.. A Journey of 1000 miles starts with 1st Step.Induction.

Volume 2B Notice to Applicants. Medicinal products for human use. Presentation and format of the dossier. Common Technical Document (CTD)

Unedited version adopted by the 45th WHO Expert Committee on specifications for pharmaceutical preparations. World Health Organization 2010

NRA FUNCTION IN CONTROLLING VACCINES IN CLINICAL TRIAL AND MARKETING AUTHORIZATION INDONESIA 2013 DVI MEETING 9 11 APRIL

Comparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE

ectd Digital Handbook Table of Contents

Working with ICH Quality Guidelines - the Canadian Perspective

Overview. Health Science Authority. Implementation of ICH guideline in Singapore. Singapore s experience

GMP Pharma BV. Netherlands

Regulatory Affairs Graduate & Postgraduate Program. Novartis Pharma AG Novartis Animal Health AG

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS (CVMP)

How companies leverage quality and quality certifications to achieve competitive advantage

The United States Pharmacopeia

Guidance for Industry. Q10 Pharmaceutical Quality System

PHARMACEUTICAL QUALITY SYSTEM Q10

An FDA Perspective on Post- Approval Change Management for PAT and RTRT

GUIDELINE ON ACTIVE PHARMACEUTICAL INGREDIENT MASTER FILE (APIMF) PROCEDURE 1 (The APIMF procedure guideline does not apply to biological APIs.

Our name ASPHALION derives from the Greek word asphaléia, alluding to values such as firmness, stability, certainty and reliability.

US DMF* TYPE III FOR FIBER BOARD DRUMS FOR PHARMACEUTICAL PACKAGINGS

Auditing as a Component of a Pharmaceutical Quality System

THE CHANGING FACE OF HEALTH CARE INFORMATION MANAGEMENT

ICH guideline Q10 on pharmaceutical quality system

Regulatory approval routes in the European System for Medicinal Products

HMPWG in the view of the NCA

Overview of Drug Development: the Regulatory Process

Pharmaceutical Quality Management System: Current Concept

POST-MASTER S CERTIFICATES in ADVANCED QUALITY ASSURANCE or REGULATORY AFFAIRS

Master of Science in Medical Writing Curriculum*

Importing pharmaceutical products to China

Guide to Fees for Veterinary Products

Roles & Responsibilities of the Sponsor

Global regulatory affairs role in the biopharmaceutical industry

RAC (US) Examination Study Checklist

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL VERSION 4.1

Overview of Pre-Approval Inspections

EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY VERSION 7

School of Pharmacy TEMPLE UNIVERSITY

GMP/Regulatory Environment in the

Pharmaceutical Engineering: The Lisbon Masters Program

Programme Guide PGDCDM

2016 Industry Survey Pursuing World Class RIM: Strategy, Measures and Priorities. Study Fast Facts

Marketing Authorization Procedures in the European Union Making the Right Choice

End of consultation (deadline for comments) 14 October Adoption by Committee for advanced therapies 15 October 2010

FACULTY OF MECHANICAL ENGINEERING. A GENERAL GUIDE TO WRITING AND DEFENDING MASTER'S THESIS MARM Industrial Engineering and Management

Application Of Quality Metrics In Determining Overall State Of Quality. & The Health Of Associated PQS FDA s Current Thinking

Post-Approval Change Management: Challenges and Opportunities An FDA Perspective

Drug Information Journal, Vol. 33, pp , /99

ANDA CHECKLIST FOR CTD or ectd FORMAT FOR COMPLETENESS and ACCEPTABILITY of an APPLICATION FOR FILING

Diagnostic Tests. Brad Spring Director, Regulatory Affairs

Extemporaneously Prepared Early Phase Clinical Trial Materials

Lifecycle CMC Management: ICH Q12 Progress to date

Key considerations for outsourcing late phase clinical research

IPEC- Americas Ongoing Projects

ACTIVE PHARMACEUTICAL INGREDIENTS COMMITTEE (APIC) ectd HOW TO DO DOCUMENT. July 2014

GLP vs GMP vs GCP Dominique Pifat, Ph.D., MBA The Biologics Consulting Group

EUROPEAN INDUSTRIAL PHARMACISTS GROUP

Harmonizing Change Control Processes Globally

A clinical research organization

GMP Issues for Start-Ups, quality in the supply chain and role of the Qualified Person (QP)

History and Principles of Good Clinical Practice

ICH Q10 Pharmaceutical Quality System (PQS)

Iron Deficiency Anemia- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment,

Validation Consultant

Pharmaceutical and Biomedical Due Diligence Checklist

-Drug Master File- Project Management Perspective. CDR Kun Shen, Pharm.D., M.S., BCPS

Quality Risk Management The Pharmaceutical Experience Ann O Mahony Quality Assurance Specialist Pfizer Biotech Grange Castle

Total Product Lifecycle Solutions from NSF Health Sciences Medical Devices

Overview of CDISC Implementation at PMDA. Yuki Ando Senior Scientist for Biostatistics Pharmaceuticals and Medical Devices Agency (PMDA)

Title: Clinical Research, Data Management and Biostatistics using SAS

THESIS AND DISSERTATION FORMATTING GUIDE GRADUATE SCHOOL

PharmAssess Audit Reports Operational Consultancy GMP Auditing Services Regulatory Affairs.

Guidance for Industry ANDAs: Stability Testing of Drug Substances and Products

Quality Agreement. by and between. Supplier Name. Address: and. Client Name: Address:

Xarelto-API Insights. Brochure More information from

Work plan for GMP/GDP Inspectors Working Group for 2016

ICH Q10 - Pharmaceutical Quality System

EDQM Certificates of Suitability: Cooperation Among Inspectorates in Europe And Beyond

ICH Public Meeting. Joseph C. Famulare. October 2, Acting Deputy Director Office of Compliance CDER / FDA Office of Compliance

The Product Review Life Cycle A Brief Overview

Changes to an Approved Product

M PHIL IN CLINICAL PSYCHOLOGY PROGRAM FACULTY OF GRADUATE STUDIES UNIVERSITY OF COLOMBO GUIDELINE FOR DISSERTATION TABLE OF CONTENTS

Thesis and Dissertation Digital Handbook

Author General Management Quality Assurance

Annex 7 Guidelines for the preparation of a contract research organization master file

Guideline on good pharmacovigilance practices (GVP)

Annex 3 Procedure for prequalification of pharmaceutical products

Good Manufacturing Practices: A Synopsis of Their Role and Rationale in Today's Pharmaceutical Marketplace for Tubing

Clinical Study Startup Timelines in Central and Eastern Europe

Transcription:

100 HOT TOPICS FOR DISSERTATION FOR PG DIPLOMA/ DEGREE IN REGULATORY AFFAIRS Mr. R.M. Gupta (M. Pharm.), is a free lancer consultant for US DMF, COS, ANDA, ACTD, CTD, ectd and he is also the director of Global Institute of Regulatory Affairs, Pune. He is also associated with Perfect Pharmaceutical Consultants Pvt. Limited (Pune, India) an organization providing regulatory solutions to Drug Industry for the last 25 years. Abstract: The Post Graduate education courses in RA generally require submission of a dissertation on some current topics in drug regulations. The quality of the dissertation indicates the knowledge and understanding of the subject matter. This article is specially written to guide RA students for selecting the most current regulatory topic and to design a powerful dissertation on the same. The students are s are invited to post their queries at guptarmg1952@gmail.com INTRODUCTION Post Graduate Training and Diploma in Regulatory Affairs is rising rapidly in India and abroad. Currently there are more than 100 Schools all over the world which imparts Post Graduate Diploma, M.Sc. or M. Pharma in RA. One of the major criteria for qualification RA is dissertation/course work/project profile of 10,000 to 15,000 words on a topic provided by the Course Director. A good dissertation shall demonstrate that the student has understood the topic from all regulatory angles. It shall be supported by references to the peer reviewed articles from literature. It may also include References to the regulatory experts who were consulted by the student to understand the practical aspects of the subject matter. The dissertation must be the original work of a single student. The topic for dissertation shall be of current importance to impact the examiner The students are advised to present the dissertation must in a clear and professional manner. Once the submission is ready it shall be self checked by the student for the following points Copyright Perfect Pharmaceutical Consultants Pvt. Limited, Oct. 2012. All rights reserved. 1

CHECKLIST FOR REGULATORY DISSERTATIONS 1 If the cover pages presents the title of the presentation, version number and name of author and the date of final editing and the date of submission. 2 If the subsequent page presents the purpose of dissertation and acknowledgements to the contributors 3 If the detailed index is provided for the presentation 4 If all the sections and sub-sections are clearly written with ample white space? 5 Does the page layout, spacing, tabular presentation, graphical presentations look professional rather than like a simple typing job? 6 Does the presentation is visually pleasant? 7 If the presentation has polished appearance 8 If the generally acceptable fonts fonts such as such Times New Roman is used through out? 9 Are the design elements such as Tables, Graphs, font size, Font types, Bolding are used appropriately for easy reading and quick capturing by the eyes? 10 If there is good balance between text and white space? 11 Are margins even on all sides? 12 Are design elements like spacing and font size used consistently throughout the document? 13 If all the pages are properly numbered and captioned and the page breaks are formatted properly? 14 Are all sections clearly captioned? 15 Are sections placed in perfect order as detailed in CTD Guidelines? 16 If the submission is specific to the scope as defined by the course director? 17 Does the data indicate the appropriate compliance with current drug regulations? 18 Do the submission uses scientific and regulatory terminology? 19 Does the submission meet all regulatory guidelines and specifications? 20 If the content flow is logical and easy to understand? 21 If the dossier is as perfect as possible, with no careless technical, typo, spelling, grammar and syntax errors? 22 If the bibliography is presented in most scientific manner 23 Does the presentation includes authors own statements 24 Does the presentation provide suitable references for the text taken from standard books, journals and regulatory guidelines? TOPIC FOR DISSERTATION WORK It must be current, novel, creative and meaningful.ideally it shall add value to the Regulatory Compliance. The selected topics may provide critical review and solutions to regulatory submissions. The followings are top most 100 topics for regulatory research and dissertation work. Copyright Perfect Pharmaceutical Consultants Pvt. Limited, Oct. 2012. All rights reserved. 2

100 TOPICS FOR REGULATORY RESEARCH AND DISSERTATION WORK 1 Similarities and Difference between US DMF, Canadian DMF and edmf 2 Similarities and Differences in Approval procedure for New Drug Application in USA and EU 3 Comparative study of New Drug Application Procedure in US,EU and India 4 Recent Advances in Regulations for Labeling and Advertising in USA 5 Common Deficiencies in Regulatory submissions 6 FDA Review Procedures for NDA,ANDA and DMF 7 EDQM Review Process for CEP 8 Role of Post Approval Clinical Trials for Drug safety 9 Resources for scientific and technical information for designing Regulatory Submissions 10 Current Deficiencies in Schedule Y 11 Current Role of GMP Audit for Marketing Authorizations of API 12 Current Regulations for Marketing Authorization of Pharmaceutical Excipients 13 Current Regulations for Marketing Authorization of Pharmaceutical Packaging Materials 14 Marketing Authorization of New Drug substance in USA 15 Marketing Authorization of New Drug substance in Europe 16 Regulatory Guidelines for Product Development 17 Critical and Comparative Analysis of Marketing Authorization Procedures in Developing Countries 18 The Role of RA in Pharmaceutical Exports 19 Risks and Opportunities in Development of New Drug 20 Question based Review of Regulatory Compliance 21 Electronic Regulatory Submissions 22 Principles and Guidelines for Regulatory Affair of Pharmaceutical Products 23 Conflicts and Solution Trends in Regulatory issues 24 Challenges and Prospects for filing CEP in Europe 25 Standard Practices in Regulatory Compliance 26 FDA 483 Notifications 27 Challenges in Regulatory Filings for Generic Products 28 Current Regulations for Herbal Products 29 Current Regulations for Biological Products 30 Role of ICH in Harmonizing Drug Regulations 31 Regulatory System in ICH Region 32 Regulatory System in ASEA 33 Regulatory System India 34 Latest Regulations for BE studies for the approval of ANDA 35 Current trends in Regulatory Actions against Misbranding and Adulteration 36 Design and development of National Drug Regulatory System and Policies 37 US Drug Regulatory System v/s European Drug Regulatory Systems 38 Challenges in designing ANDA for Parenteral Products Copyright Perfect Pharmaceutical Consultants Pvt. Limited, Oct. 2012. All rights reserved. 3

39 Challenges in designing CEP on Anticancer Products 40 Challenges in drafting CTD Module 2 (Clinical and Nonclinical Summary) 41 Strategy for Regulating Regulatory Functions 42 Role of Regulatory Affairs in Marketing Pharmaceutical products 43 Regulatory strategy for filing NDA/ ANDA 44 Regulatory strategies for successful pan-european registration 45 Strategic Planning for Regulatory submissions 46 The effective strategies for interactions with Regulatory Agencies 47 The commercial aspects of regulatory approvals 48 Electronic Common Technical Document submissions 49 Interrelationship between Regulatory Affairs, Quality Control and Quality Assurance for regulatory submissions 50 Regulatory issues for import of Pharmaceutical Products into India 51 Regulatory issues for export of Pharmaceuticals products to Latin America 52 Regulatory issues for export of Pharmaceuticals products to countries under ROW 53 Malpractices in Regulatory Submissions (MRS) 54 ICH Guidelines for Impurity Profiling 55 Role of Training in Regulatory Compliances 56 Principle of Regulatory Compliance (PRC) 57 Market authorizations in Latin America 58 Life Cycle of Drug Regulations (LCDR) 59 Latest Trends in Regulatory Compliance Training 60 Current Trend in Liaison with Regulatory Authorities 61 Current Trends in Regulatory Projects Management 62 Regulatory Aspects of Contracts Manufacturing 63 Pharmacopeial Standards for API 64 Current Trends in Review of CTD Dossiers 65 CEP Project Management 66 Mutual Recognization Procedures (MRP) 67 MAA Project Management 68 Product Registration Strategies 69 Current Appraisal Procedures for New Regulations, Standards, Policies, and Guidance issued by Regulatory Authorities 70 Current Trends in Planning, Preparation and Delivering Regulatory Submissions 71 Current Regulations for Variation Filings for the registered products 72 Good Practices in Evaluation and solutions to the deficiencies in CTD Submissions 73 Good Practices in updating Regulatory Filings. 74 Current Trend in follow-up procedures with MOH for the registration of Pharmaceutical products 75 Current Regulations for labeling and Advertising of Medicinal products 76 Good Practices for the Management of Quality Audits conducted by Regulatory Authorities 77 Good Practices in Management of comments/deficiencies in CTD/ACTD 78 Knowledge Management in RA (KMRA) 79 International Regulatory Framework (IRF) Copyright Perfect Pharmaceutical Consultants Pvt. Limited, Oct. 2012. All rights reserved. 4

80 Review and Approval Procedures for Promotional Materials 81 Regulatory Practices in CIS Countries 82 Current Regulations for Clinical Trials 83 Role of COPP in Pharmaceutical exports 84 Risk Analysis of Regulatory Non Compliance 85 Current Compendia Standards for Drug Products 86 Current Compendia Standards for API 87 Review of Responsibilities and Expectations from RA Professionals 88 Self Audit procedures for Regulatory Compliance Issues 89 Latest trends in Archiving of Regulatory Submissions 90 Corrective and Preventive procedures for Regulatory Compliance 91 Review of Regulatory Guidelines available on Web 92 Review of Free Regulatory Knowledge Resources on Web 93 Current Practices in Solving Complex Regulatory matters 94 Trends in the Management of Relations with Health authorities 95 Role of QMS (Quality Management System) for effective Regulatory Compliance 96 Master Regulatory Compliance Program (MRCP) 97 Recent Developments in Regulatory Compliance Strategies, 98 FDA Litigation Procedures for Regulatory Noncompliance 99 Annual Regulatory Compliance/Noncompliance Review Procedures 100 Trends in designing chemistry, manufacturing and controls (CMC) components of regulatory submissions 101 Recent trends in Training Regulatory Project Team Members, Cross functional teams, Senior management and Regulatory consultants associated with the company. 102 Patent issues in ANDA Approval 103 Good Practices in Organizing Regulatory Compliance Projects 104 Management of NC Reports /Queries issued by MOH 105 Review of the Current Status of Schedule Y 106 Good Regulatory Compliance Practices (GRCP) ASSESSMENT OF DISSERTATION AT GIRA The overall aim of the dissertation is to train the student for deep understanding of the regulations to resolve complex regulatory problems most economically, rapidly and to the full satisfaction of the regulatory authorities Assessment of dissertation is a complex affair. At GIRA all dissertation are critically checked for presentation and basic understanding of the project by a Primary Regulatory Expert and by Course Director. Please refer the Annexure for the format used by GIRA for dissertation assessment. Copyright Perfect Pharmaceutical Consultants Pvt. Limited, Oct. 2012. All rights reserved. 5

CONCLUSION Dissertation writing is a critical element for Graduate/Post Graduate Course in RA. Dissertation is an evaluation of Intelligent Quotient and Regulatory Knowledge of RA students. The topic for the dissertations shall be of current importance and the presentation must display deep understanding of the relevant regulations. Note: For any help on dissertation design, writing and evaluation please contact the author Rajkumar M. Gupta Managing Director- Perfect Pharmaceutical Consultants Pvt.Ltd Director-Global Institute of Regulatory Affairs (GIRA) Drug Regulatory Affairs Consultant and Regulatory Affairs Trainer (CTD, ectd, DMF,CEP, ANDA Designer and Reviewer) Regd. Office: - Prestige Classic (D Wing) Dawa Bazar, Pune Mumbai Express Highway, Chinchwad, Pune 411019, Maharashtra, India. Contact Mobile No.:- +91-9371020504 E-Mail:- guptarmg1952@gmail.com Web: www.regulatoryinstitute.com Article Links - https://sites.google.com/site/ppcdmf/announcements Copyright Perfect Pharmaceutical Consultants Pvt. Limited, Oct. 2012. All rights reserved. 6

APPENDIX DISSERTATION EVALUATION FORM AT GIRA (Subject: ) No. Parameter Marks Allotted 1. Presentation 15 - Proper Index/ Numbering/ 5 Printing Layout - Use of Diagrams/ 5 Flow charts - Grammatical Errors 5 2. Content 20 - Technical content covered 10 - Depth of information 5 - Correctness/ Relevancy of 5 the information 3. Referencing 10 - Proper referencing 5 - Use of own language 5 4. Creativity/ Overall Conclusion 5 Total 50 Primary Evaluation Secondary Evaluation Result (Average): /50 ( grade) A Grade > 40 /50 B Grades 30 40 /50 C Grade 20 30 /50 Date and Sign and Comments by of Primary Evaluator Date and Sign and Comments by Secondary Evaluator Copyright Perfect Pharmaceutical Consultants Pvt. Limited, Oct. 2012. All rights reserved. 7